Statins × cardiovascular events

TrialEuropean heart journal2011

The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K.

Peter S Sever et al.PubMed ↗Publisher ↗

What the trial testedrandomised · 520 people · 2011

Randomised comparison

Probably reduced deaths

−14%−24% to −2%

Bigger than 4 in 10 for all-cause mortality

As reported

HR 0.86, 95% CI 0.76–0.98 · the paper's word: All-cause mortality

Randomised comparison

Probably reduced cardiovascular events

−15%−27% to −1%

Bigger than 3 in 10 for cardiovascular events

As reported

HR 0.85, 95% CI 0.73–0.99

Range includes no effect

No clear effect on cardiovascular events

−11%−28% to +11%

Bigger than 2 in 10 for cardiovascular events

As reported

HR 0.89, 95% CI 0.72–1.11

Three numbers in the abstract

the abstract, start to end

originally assigned atorvastatin (HR 0.86, CI 0.76-0.98, P=0.02).

were fewer, but not significant (HR 0.89, CI 0.72-1.11, P=0.32) and non-CV deaths were significantly lower (HR 0.85, CI 0.73-0.99, P=0.03) in those

← favours treatmentfavours comparator →
could be chance
All-cause mortality
HR 0.860.76–0.98
Cardiovascular events
HR 0.890.72–1.11
Cardiovascular events
HR 0.850.73–0.99
StatinsCardiovascular eventsAll-cause mortality

Statins × cardiovascular eventshelps?replicated

unlikelylikely
0.860.86 without it

Statins × all-cause mortalityhelps?mixed

unlikelylikely
0.500.48 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

50 papers cite it

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 21873710